| 名称 | COTI-2 |
| 描述 | COTI-2, an orally available thiosemicarbazone, is an activator of mutant forms of the p53 protein with potential antineoplastic activity. |
| 细胞实验 | COTI-2 is dissolved in 100% dimethyl sulfoxide stock solution and diluted in medium plus FBS such that final DMSO concentrations are 0.5 to 1.0% depending on the experiment.SHP-77 cells are cultured with various concentrations of COTI-2 for 48 h. Cells are then washed twice with 1× cold PBS and stained with Annexin V and 7AAD according to the manufacturer's instructions. Briefly, 5 μL of Annexin V and 7AAD are added to 1×105 cells and incubated for 15 min at room temperature in the dark. Then 400 μL of the 1× binding buffer (100 mM HEPES, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) is added to the cells. Finally, cells are analyzed using a flow cytometer. |
| 激酶实验 | The interaction of COTI-2 with 227 kinases is tested using the AMBIT BIOSCIENCES KINOMESCAN assay. In brief, streptavidin-coated magnetic beads are treated with biotinylated small molecule ligands for 30 min at 25°C to generate affinity resins for kinase assays. The liganded beads are blocked with excess biotin and washed with blocking buffer (1% BSA, 0.05% Tween 20, 1 mM DTT) to remove unbound ligand and to reduce non-specific binding. Binding reactions are assembled by combining phage lysates, liganded affinity beads, and COTI-2 in 1× binding buffer (20% SeaBlock, 0.17× PBS, 0.05% Tween 20, 6 mM DTT). All reactions are carried out in polystyrene 96-well plates that have been pre-treated with blocking buffer in a final volume of 0.1 mL. |
| 动物实验 | SHP-77 and HT-29 cells are injected in 50% matrigel into flanks of NCr-nu mice (2×106 cells per injection site) (n=5 mice per group). In the case of SHP-77 xenografts, treatment with COTI-2 begins prior to the appearance of palpable tumors. One day after injection of SHP-77 cells, animals receive 3 mg/kg of COTI-2 (once every two days, up to 38 days). Tumor sizes are estimated at 5, 10, 17, 24, and 38 days, by standard caliper measurements. In the case of HT-29 xenografts, the capacity of COTI-2 to suppress the growth of established tumors is assessed. HT-29 xenografts are allowed to grow to 200 mm3 before starting IP treatment with COTI-2 (10 mg/kg, 5 days a week for 7 weeks) or saline IP. Tumor growth is measured every 4 days by caliper measurement. |
| 体外活性 | COTI-2（72小时）显著抑制了所有测试细胞系的增殖速率。在COLO-205、HCT-15和SW620细胞系中，COTI-2显著抑制肿瘤细胞增殖。COTI-2的相对低浓度对所有测试的人类胶质母细胞瘤细胞系（U87-MG、SNB-19、SF-268和SF-295）均有效。在SHP-77细胞中，COTI-2处理的IC50浓度导致40至47%的总细胞发生早期凋亡。 |
| 体内活性 | 在HT-29人类结直肠癌异种移植模型中，COTI-2（10 mg/kg）显著抑制肿瘤生长。不仅在特定治疗后时间点减少肿瘤体积，COTI-2还延长肿瘤达到特定体积的时间。在SHP-77 SCLC异种移植模型中，COTI-2（3 mg/kg）同样显著抑制肿瘤生长。COTI-2能在特定治疗后时间点减少U87-MG肿瘤体积，并延长U87-MG异种移植体在裸鼠体内生长所需的时间。仅用载体处理的对照组小鼠的肿瘤，5天内就达到平均体积828 mm3，而用COTI-2处理的动物肿瘤需要双倍时间（10天）达到类似的平均体积（857 mm3）。无论采用何种给药途径，COTI-2均强效抑制OVCAR-3异种移植体的生长。 |
| 存储条件 | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | DMSO : 5 mg/mL (13.64 mM), Sonication is recommended.
|
| 关键字 | toxicity | TNBC | p53 | orally | MDM-2/p53 | low | Inhibitor | inhibit | HNSCC | COTI-2 | Apoptosis | anti-proliferative | anti-cancer |
| 相关产品 | Urea | Dimethyl phthalate | Aceglutamide | Alginic acid | Cysteamine hydrochloride | Metronidazole | Dextran sulfate sodium salt (MW 5000) | Citric Acid Triammonium | Gum arabic | Stavudine | Tamoxifen | Sodium 4-phenylbutyrate |
| 相关库 | 抗癌活性化合物库 | 经典已知活性库 | 已知活性化合物库 | 抗结直肠癌化合物库 | 抗衰老化合物库 | HIF-1化合物库 | NO PAINS 化合物库 | 泛素化化合物库 | 抗肺癌化合物库 | 药物功能重定位化合物库 | 抗癌临床化合物库 | 抗癌药物库 |